TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05230277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the active osteopathic treatment (AOT)
Description: The AOT will first consist of the application of a visceral technique. The patient will lie on their stomach and the osteopath will touch the patient's abdomen with a wide two-handed grip. The action will consist of following the abdominal tissues in directions where tissue mobility is allowed and occurs without restriction, from the surface to the depth of the abdomen. A change in the elasticity of the colon will then be perceived when the mobility restrictions of the tissues are dissipated. The osteopath will then use a technique on the sacrum according toik-g the procedure described by Attali et al. \[8\] which consists in mobilizing the sacrum between the iliac bones.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: the sham osteopathic treatment
Description: For SOT, the patient will lie on their stomach and the osteopath will use a wide two-handed grip on the patient's abdomen to deliberately mobilize it in an imprecise manner. Next, a technique with no apparent therapeutic effects, the light touch, first described by Licciardone et al. \[13\] and proposed by others to perform simulated bone manipulations \[14\], will be applied to the sacrum
Study: NCT04851730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthopedic Physical Therapy Intervention
Description: First, a deep slow breathing protocol is intended to increase the expansion of the pelvic floor, utilizing the relationship between the diaphragm and the pelvic floor, resulting in a gentle stretching of the pelvic floor.~Next, abdominal soft tissue mobilization, or scar mobilization of the lumbopelvic abdominal area will take place.~Next, manual therapy to the thoracic or lumbar spine or the hips will be performed based on the impairments found in the orthopedic evaluation.~The participant will be given a home exercise program to support breath training, and manual therapy. During the initiation of the second visit each participant will watch a standardized pain education video on the tablet, Understanding pain in less than 5 minutes and what to do about it The above plan of care will be completed 2 times/week for 4 weeks for a total of 8 visits.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Third, the investigator will dry needle appropriate muscles. Dry needling treatment technique will include insertion of a sterile, disposable, solid filament needle into the muscle belly in the area palpated as listed below. A 0.30 × 0.50mm, or specified size below, stainless steel Seirin J-type or Myotech needle will be used (Dommerholt 2011). Clean technique will be employed throughout the treatment procedure which includes hand washing, clean latex-free glove use, and skin-surface preparation with an alcohol swab ( Baima \& Isaac 2008). Each muscle will receive a maximal number of 2 insertions and each insertion consists of up to 5 seconds of a pistoning (in and out motion) technique in an attempt to elicit a local twitch response. Standard protocol for each muscle will be established prior to beginning data collection.~Details about the dry needling protocol can be found in Appendix L.
Study: NCT04844333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extubation under deep anesthesia
Description: When the patient in sedation or anesthesia state, no body movement, bispectral index 60-70, spontaneous breathing recovery, VT ≥ 5ml / kg, respiratory rate 10-20 times / min, regular rhythm, PetCO2 \< 45mmhg, regular waveform, stable circulation, the patient is in deep anesthesia state, and the endotracheal tube is removed.
Study: NCT05214235

Intervention type: DRUG
Intervention: Hypoglycemic Drugs
Description: Patients were divided into metformin group and sitagliptin group according to the type of hypoglycemic drugs they took.
Study: NCT06437314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic program based on the back school
Description: Participants will undertake a back school-based program. This program will follow the recommendations of the biopsychosocial model of chronic pain and will be conducted in an aquatic environment. The intervention will be carried out by physiotherapists in a sports center. The duration of the intervention will be six weeks, with a frequency of two sessions per week, totaling 12 sessions of 45 minutes each. Of all the sessions, 10 will have a practical focus (centered on trunk exercises) and the other two will have a theoretical focus (providing education on pain and risk factors for low back pain).
Study: NCT05672745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WB-LIFE
Description: WB-LIFE is a mobile application program grounded in validated psychotherapies (including cognitive behavioral therapy, interpersonal, and dialectical behavioral therapy), that enlists the relational agent Woebot to guide users in managing their mood. The user experience is driven by artificial intelligence and centers around mood tracking, evidence-based tools, and goal-oriented, tailored conversations.
Study: NCT05189678

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06428396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan 120 mg administered QD as an oral tablet.
Study: NCT05021887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals
Description: 2 inhalations of Test and Reference product in each study period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOVENT DISKUS
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT05336435

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Implementation of the new population and sex-specific 99th percentile URL for cardiac troponin
Description: The new population and sex-specific 99th percentiles URLs will be implemented at all Danish hospitals receiving patients with chest pain for initial diagnostics for possible acute MI. This will take place as a randomized step-by-step introduction of population and sex-specific 99th percentile URLs for troponin in all hospital centers with a monthly start time interval. Each center is randomized to shifting from the sex-uniform manufacturer provided 99th percentile URL of cardiac troponin currently used nationwide to the new population and sex-specific 99th percentiles URLs provided by the DANSPOT study's first phase.
Study: NCT04934852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 4 mg ephedrine in 10 ml saline was usd Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 8 mg ephedrine in 10 ml saline was usd Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: When elderly patients had hypotension (invasive blood pressure drops \>20% from the baseline value or \<100 mmHg, or MAP \<70mmHg) 20 minutes after anesthesia induction, 12 mg ephedrine in 10 ml saline was usd Intravenously
Study: NCT04380545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alpha 2b-like Protein
Description: Given SC
Study: NCT05298592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986406
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986406
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986406
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986406
Description: Specified dose on specified days
Study: NCT04964479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 injection
Description: 1200mg injection once every 3 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsules
Description: 12mg capsule once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab injection
Description: 200mg injection once every 3 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once daily
Study: NCT06331871

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guied Percutaneus Electrical Nerve Stimulation (US-PENS) and Manual physiotherapy protocol based on available evidence.
Description: Intervention performed by needling in the vicinity of the peripheral nerves of the shoulder under ultrasound-guided control.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual physiotherapy protocol based on available evidence.
Description: Physiotherapy treatment based on the best scientific evidence available, based on manual therapy and passive and active kinesitherapy
Study: NCT05515042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)
Description: As included in arm/group descriptions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)
Description: As included in arm/group descriptions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer)
Description: As included in arm/group descriptions
Study: NCT05298592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986406
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT06428396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg administered as an IM injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg administered as an IM injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Administered at 10mg via oral tablets QD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Administered at 25 mg via oral tablets QD.
Study: NCT05743309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video call sessions
Description: Investigators made video call sessions with the participants.
Study: NCT05320367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis, placebo
Description: Eligible participant will be randomize 1:1:1:1:1 to receive placebo, CBD (5mg, 20mg, 50mg and 100mg). Only one research product will be inhaled for each visit. The sequence will depend on the assigned randomization group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis, placebo
Description: Eligible participant will be randomize 1:1:1:1:1 to receive placebo, CBD (5mg, 20mg, 50mg and 100mg). Only one research product will be inhaled for each visit. The sequence will depend on the assigned randomization group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis, placebo
Description: Eligible participant will be randomize 1:1:1:1:1 to receive placebo, CBD (5mg, 20mg, 50mg and 100mg). Only one research product will be inhaled for each visit. The sequence will depend on the assigned randomization group.
Study: NCT04930393

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Block - either PECS II or axillary ring
Description: In addition to an interscalene nerve block, one of these two interventions will be administered to assess pain control after a biceps tenodesis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve Block - either PECS II or axillary ring
Description: In addition to an interscalene nerve block, one of these two interventions will be administered to assess pain control after a biceps tenodesis
Study: NCT01063686

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: insemination cervical cap
Description: Primary abdominal ultrasound (US) for amniotic fluid index (AFI), Single vertical pocket, and dimensions of pocket below the presenting part. Speculum vaginal examination. In a sterile manner a cervical cap is adjusted on the cervix. the patient is kept recumbent for 6 hours. A repeat US exam is performed. The cervical cap is removed. After one hour another US is performed.
Study: NCT06631495

Intervention type: OTHER
Intervention: Observation
Description: not available-observation study
Study: NCT06628518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAmily oriented Mindfulness informed Legal Education (FAMiLE)
Description: The FAmily oriented Mindfulness informed Legal Education (FAMiLE) is a low-intensity intervention involving four sessions. The session will cover relevant aspects of brief mindfulness, legal education, awareness of human rights and challenges of complaint, including support. The Family oriented component will include stress management, including coping techniques and problem-solving, positive communication, behaviour modification and parenting, and a session on consolidation including sustaining gains. The intervention will also incorporate positive parenting and interactions with children.
Study: NCT05483374

Intervention type: OTHER
Intervention: observation
Description: Not applicable, it is an observational registry

Intervention type: OTHER
Intervention: observation
Description: Not applicable, it is an observational registry

Intervention type: OTHER
Intervention: observation
Description: Not applicable, it is an observational registry

Intervention type: OTHER
Intervention: observation
Description: Not applicable, it is an observational registry
Study: NCT06376214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplantation (ASCT)
Description: The ASCT protocol included mobilisation with colony-stimulating factor alone and conditioning with high-dose melphalan140-200 mg/m2~.
Study: NCT04960345

Intervention type: DEVICE
Intervention: Brainlab Knee 3
Description: Brainlab knee 3 navigation system is a kind of imageless computer-assisted navigation system.
Study: NCT05681195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants will receive 900 mg/m\^2 via IV infusion over 10 minutes every 3 weeks x 4-8 induction cycles (21 days per cycle) as part of the induction therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Participants will receive 320 mg PO daily or dose-adjusted when given concomitantly with CYP3A4 inhibitor on Days 3-19 of each induction cycle x 4-8 cycles (21 days per cycle) as part of the induction therapy.~For those on maintenance therapy, participants will receive 320 mg PO daily or dose-adjusted when given concomitantly with CYP3A4 inhibitor on Days 1-28 of each maintenance cycle (28 days per cycle) until the transplant (if applicable) or disease progression.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant (ASCT)
Description: ASCT will occur in participants who are candidates for this procedure according to standard of care institutional protocols

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiation Therapy (WBRT)
Description: WBRT will occur in participants who are candidates for this procedure but not candidates for ASCT according to standard of care institutional protocols
Study: NCT05298592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Specified dose on specified days
Study: NCT05434130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Dose Exercise
Description: The investigators will initially test and randomize adolescents ages 13-18 years old ≤14 days post-concussion to high dose aerobic exercise (\>150 min/week, individualized intensity level) or standard-of-care (symptom limited, self-guided physical activity), and re-test upon symptom resolution and 8-weeks post symptom resolution
Study: NCT04084574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH diet counseling
Description: Culturally-appropriate, disease-sensitive counseling intervention to enhance DASH diet adherence in Blacks with CKD compared to standard of care condition

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DASH diet counseling
Description: Culturally-appropriate, disease-sensitive counseling intervention to enhance DASH diet adherence in Blacks with CKD compared to standard of care condition
Study: NCT05320367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis, placebo
Description: Eligible participant will be randomize 1:1:1:1:1 to receive placebo, CBD (5mg, 20mg, 50mg and 100mg). Only one research product will be inhaled for each visit. The sequence will depend on the assigned randomization group.
Study: NCT06553573

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parasternal Block and Recto-İntercostal Fascial Plane Block
Description: Parasternal Block and Recto-Intercostal Fascial Plane Block:Superficial PSB is performed bilaterally with the patient in the supine position using a high-frequency linear USG probe. The probe is inserted longitudinally 2cm lateral to the sternal border to visualize the T2T4 intercostal space and identify the pectoralis major muscle, intercostal muscle, and pleura. Using an in-plane approach with a 100mm needle, 10ml of 0.25% bupivacaine is administered between the pectoralis major and intercostal muscle. Additionally, a Recto-Intercostal Fascial Plane Block is performed bilaterally with a high-frequency linear USG probe. The probe is inserted 2-3cm lateral to the xiphoid to visualize the rectus abdominis muscle and the 6th-7th cartilages. The needle is advanced to the plane between the costal cartilage and the rectus abdominis muscle using the in-plane technique, and 1-2ml of saline is injected. After spreading to the target plane is observed, 20ml of 0.25% bupivacaine is administered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parasternal Block and Erector Spinae Plane Block
Description: Superficial PSB is performed with the patient in the supine position using a high-frequency linear USG probe. The probe is placed longitudinally 2cm lateral to the sternal border to identify the T2T4 intercostal space, pectoralis major muscle, intercostal muscle, and pleura. Using an in-plane approach with a 100mm needle, 10ml of 0.25% bupivacaine is applied between the pectoralis major and intercostal muscle. Additionally, an erector spinae plane block is performed with a high-frequency USG probe. Erector spinae plane block is performed under general anesthesia, in the lateral position, under USG guidance, after sterilization, by inserting a needle between the deep surface of the erector spinae muscle and the transverse process with an in-plane approach in the craniocaudal direction. If no air or blood is seen in the aspiration, a 2mL serum test dose is applied to this area and a total of 20mL of 0.25% bupivacaine is injected bilaterally to perform an erector spinae plane block.
Study: NCT06112119

Intervention type: DEVICE
Intervention: MSCT
Description: Using Semi-automatic MSCT Volumetry in assessment of brain atrophy associated with septic ICU patients
Study: NCT04536077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-301
Description: The drug will be supplied free of charge by Celldex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1140
Description: The drug will be supplied free of charge by Celldex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1140
Description: The drug will be supplied free of charge by Celldex

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: At screening; prior to first therapeutic dose of CDX-1140, on the day of the infusion; and at the time of surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: At screening; prior to first therapeutic dose of CDX-1140, on the day of the infusion; and at the time of surgery
Study: NCT05821127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Assisted Neurodynamic Exercises and Patient Education with Telerehabilitation Method
Description: A brochure showing the execution of median nerve and tendon gliding exercises and a wrist brace for night use will be provided. In addition, 2 sessions of patient education will be provided with videoconference calls, and with the mobile application to be installed on the phones of the patients as non-immersive virtual reality support, it will be possible to practice median nerve and tendon gliding exercises in the form of 5 repetitions and 6 sets every day with video support for 16 weeks. In this application, the user will use the front camera of phone as a sensor to detect hand movements. A screen on which exercises will be played at the top of the screen and a virtual image of the user's hand in the lower half of the screen will be displayed in the field of view of the camera. Each exercise position will take 5 seconds. Patient education will include neuroscience, etiology, pathophysiology and treatment options of carpal tunnel syndrome, ergonomics and posture education.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurodynamic Exercises and Patient Education with Traditional Method
Description: A brochure showing the execution of median nerve and tendon gliding exercises and a wrist brace for night use will be provided. Patients will be asked to do the exercises in the form of 5 repetitions and 6 sets every day and to wear the night splint every night for 16 weeks. Each exercise position will take 5 seconds. A brief verbal education will be given to the patients under the same topics as the intervention group, as in the outpatient clinic.
Study: NCT05249972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)
Description: Topical cutaneous spray
Study: NCT04878627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: patients receive cannabidiol at various doses for 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients receive placebo for 3 weeks